NasdaqGS:IBRXBiotechs
Did ANKTIVA’s Early Revenue Surge and Compliance Strains Just Shift ImmunityBio’s (IBRX) Investment Narrative?
ImmunityBio recently reported preliminary first-quarter 2026 net product revenue of about US$44.2 million, an approximately 168% year-over-year increase, alongside continued international rollout of its bladder cancer therapy ANKTIVA across roughly 34 countries.
At the same time, the company is working through FDA promotional compliance issues and related securities class actions, while emphasizing corrective measures and stronger internal controls around how ANKTIVA’s benefits are...